The peach-potato aphid, Myzus persicae, is a serious crop pest that has developed imidacloprid resistance, mainly through overexpression of CYP6CY3. Here, we established a metabolic assay using Drosophila S2 cells that stably expressed CYP6CY3. We found that CYP6CY3 showed metabolic activity against imidacloprid, as well as acetamiprid, clothianidin, and thiacloprid, but had no activity against dinotefuran. Our study suggested that stable gene expression in Drosophila S2 cells is useful for examining which insecticide is metabolized by P450 monooxygenases.
Introduction
The peach-potato aphid, Myzus persicae, is a globally important crop pest. Imidacloprid was launched in 1991 and showed excellent efficacy against M. persicae. 1) However, the subsequent heavy use of this insecticide combined with M. persicae feeding on tobacco containing nicotine led to this pest developing resistance to imidacloprid. 2) Imidacloprid acts as a nicotinic acetylcholine receptor (nAChR) competitive modulator and belongs to Insecticide Resistance Action Committee (IRAC) Group 4A (http://www.pestcideresistance.org), which currently contains seven neonicotinoids: imidacloprid, nitenpyram, acetamiprid, thiamethoxam, thiacloprid, clothianidin, and dinotefuran.
The most common mechanism of imidacloprid resistance is the overexpression of the P450 monooxygenase enzyme CYP6CY3. 2, 3) In addition, a target point mutation of R81T in the nAChRβ1 subunit was found in M. persicae collected from France in 2009. 4) However, individuals carrying this mutation have only been found in southern Europe (Italy, France, and Spain) [4] [5] [6] and are less common than individuals overexpressing CYP6CY3. 7, 8) While the R81T mutation confers cross-resistance to a range of IRAC Group 4 chemicals, including neonicotinoids (Group 4A), sulfoxaflor (Group 4C), flupyradifurone (Group 4D), and triflumezopyrim (Group 4E), 9) the overexpression of CYP6CY3 has only been reported to confer resistance against neonicotinoids belonging to IRAC Group 4A. 3) There is wide variation in the resistance of M. persicae to different neonicotinoids. For example, resistance ratios for the FRC strain, in which neonicotinoid resistance is caused by the overexpression of CYP6CY3 and the R81T mutation, 4) range from >2500 for imidacloprid, clothianidin, and thiacloprid to >100 for thiamethoxam and nitenpyram, >80 for acetamiprid, 54 for dinotefuran, and 43 for sulfoxaflor. 10) It is noteworthy that there is the same level of resistance to dinotefuran and sulfoxaflor, despite these being classified as subgroups 4A and 4C, respectively.
To better understand why M. persicae has a lower resistance to dinotefuran compared with other neonicotinoids belonging to IRAC Group 4A, we established Drosophila melanogaster S2 cells stably expressing CYP6CY3 and measured the metabolic activity of CYP6CY3 against dinotefuran and other neonicotinoids.
Materials and Methods

Chemicals
Dinotefuran was synthesized at Mitsui Chemicals Agro, Inc. (Chiba, Japan) with a purity of >99%. Other neonicotinoids (imidacloprid, acetamiprid, clothianidin, and thiacloprid) were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan) as analytical standards with purities of >98%.
Metabolism of neonicotinoids by CYP6CY3 stably expressed in
Drosophila S2 cells DNAs for M. persicae CYP6CY3 (GenBank accession number HM009309), enhanced green fluorescent protein (EGFP) (GenBank accession number U55762), and D. melanogaster Nicotinamide-adenine dinucleotide phosphate (NADPH) cytochrome P450 reductase (CPR) (GenBank accession number X93090) were obtained via gene synthesis (GenScript, Tokyo, Japan). The synthesized DNAs were then inserted into the expression vector pAc5.1-lac-Hygro as previously described. 11) Drosophila S2 cells stably expressing CYP6CY3, CPR, and EGFP were constructed as described previously. 11) S2 cells were seeded in a 60 mm dish (2×10 6 cells/well) and incubated in 4 mL of Express Five medium (Invitrogen) for 20 min at 25°C. The transfection-mix containing 6 µg of DNA and 8 µL of cellfectin (Invitrogen) in 200 µL of Express Five medium was added to S2 cells in a 60 mm dish. Twenty-four hours after transfection, the medium was replaced with 4 mL of Express Five medium supplemented with 1% fetal bovine serum (FBS) and 200 µg/ mL hygromycin B. Transfected cells were cultured for at least 3 weeks to confirm the expression of EGFP and CYP6CY3. Expression of EGFP in S2 cells was confirmed via fluorescence microscope (MRC1024; Bio-Rad, Hercules, CA, USA). The expression of CYP6CY3 in S2 cells was confirmed by the metabolism of imidacloprid. The metabolism of neonicotinoids was assayed as described below. S2 cells transfected with CYP6CY3, CPR, and EGFP genes were seeded in 24-well plates (4×10 6 cells/well) and cultured in 500 µL of Express Five medium supplemented with 1% FBS, 200 µg/mL hygromycin B, 2.5 µg/mL hemin, and each 1 µM neonicotinoid at 28°C. The medium containing neonicotinoids was sampled after 0 hr and 96 hr of incubation and the samples were diluted with an equal volume of acetonitrile (300 µL total volume), vortexed for 10 sec, and centrifuged at 14,000×g for 5 min at room temperature. The supernatant was then analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (see below).
LC-MS/MS analysis
A high-performance liquid chromatograph (LC800; GL Science, Tokyo, Japan) coupled with a triple quadrupole mass spectrometer detector (API3200QTRAP; SCIEX, Tokyo, Japan) was used for quantification of the target compounds. The supernatant (1 or 2 µL) that was prepared in the metabolic assay was inject-ed into an analysis column (Atlantis T3, 2.1×100 mm; Nihon Waters, Tokyo, Japan) maintained at 40°C under isocratic conditions with a flow rate of 0.2 mL/min. The mobile phase was a mixture of water and methanol containing 0.1% formic acid at a ratio of 40 : 60 (v/v) for all neonicotinoids except dinotefuran (30 : 70, v/v). The mass transition parameters of the LC-MS/MS system operated in multiple reaction monitoring mode are presented in Table 1 .
Results and Discussion
It has been reported that imidacloprid is metabolized by M. persicae CYP6CY3. 2) However, there has been no report on the metabolic activity of CYP6CY3 against dinotefuran. In the present study, we first established Drosophila S2 cells stably coexpressing CYP6CY3 and CPR. We found that the metabolite was generated at a low level ( Fig. 1A ) and imidacloprid only decreased to 82% even after 4 days of culture ( Fig. 1B ), suggesting that CYP6CY3 was expressed at a low level. Therefore, although there was no reduction in dinotefuran (Fig. 1B) , its metabolism needed to be examined under conditions where imidacloprid was more highly metabolized. The analysis using LC-MS/MS showed that the derived metabolite weighed 16 units more than its parent compound, imidacloprid. As shown in the previous paper, 2) the metabolite seemed to be 5-hydroxy-imidacloprid. However, further studies are required to determine the structure of the metabolite by using the same structural compound as the metabolite.
To increase the expression level of CYP6CY3, only the CYP-6CY3 gene was introduced to the S2 cells based on the assumption that if endogenous CPR is sufficient for CYP6CY3 activity, the metabolism of imidacloprid should be increased. As expected, these S2 cells generated higher metabolite levels than those that co-expressed CYP6CY3 and CPR ( Fig. 2A) and imidacloprid decreased to 55% after 4 days of culture (Fig. 2B ). Under this condition, no dinotefuran is metabolized (Fig. 2B) , indicating that M. persicae with imidacloprid resistance obtained by the overexpression of CYP6CY3 will not show strong resistance to dinotefuran. As is the case of B. tabaci CYP6CM1, 12) it is possible that the binding of dinotefuran to CYP6CY3 is weak. Thus, the lack of metabolism of dinotefuran explains why the FCR strain has the same level of resistance against dinotefuran and sulfoxaflor. 10) It is noteworthy that the resistance ratios in the FRC strain exceed 2500 for imidacloprid, 10) which is metabolized by CYP6CY3. 2) Thus, it is expected that imidacloprid-resistant M. persicae will not show cross-resistance to dinotefuran due to the overexpression of CYP6CY3.
In addition to imidacloprid, 28% of acetamiprid, 60% of clothianidin, and 73% of thiacloprid were metabolized by CYP-6CY3 in this assay (Fig. 2B) . The resistance ratios of the FRC strain against imidacloprid, clothianidin, and thiacloprid are >2500, while that against acetamiprid is >80, 10) suggesting that the metabolism by CYP6CY3 greatly affects cross-resistance in this strain. The FRC strain carries the R81T mutation, which will also affect the resistance ratios. Therefore, further studies are required to elucidate the effects of the metabolic activities of CYP6CY3 on the resistance ratios.
The metabolic activities of CYP6CY3 against imidacloprid and clothianidin have been examined using microsomes prepared from Sf9 cells infected with baculovirus. 2) However, although this assay is suitable for measuring catalytic activity, the conditions needed to be adjusted for the expression of P450s, such as in the determination of the multiplicities of baculovirus infection. Consequently, Drosophila S2 cells that transiently expressed P450 genes were cultured with neonicotinoids to examine the metabolism of neonicotinoids by P450s more quickly. 13, 14) In the present study, we established Drosophila S2 cells stably expressing CYP6CY3, providing an easier and more reproducible assay. Therefore, this assay is useful for examining which insecticide is metabolized by P450 monooxygenase to confer insecticide resistance.
